METTL5在口腔鳞状细胞癌的表达及功能研究

口腔生物医学 ›› 2025, Vol. 16 ›› Issue (1): 20-25.

METTL5在口腔鳞状细胞癌的表达及功能研究

冯星雨¹,张伟¹,张双越²

1. 南京医科大学附属淮安第一医院
2. 南京医科大学附属淮安第一人民医院

收稿日期:2024-11-15 修回日期:2024-12-03 出版日期:2025-02-25 发布日期:2025-03-07
通讯作者: 张双越 E-mail:hayyzhshy@njmu.edu.cn
基金资助:
淮安市科技局项目;南京医科大学科技发展基金

Expression and function of METTL5 in oral squamous cell carcinoma

Yu XingFeng¹, Shuang-Yue ZHANG

Received:2024-11-15 Revised:2024-12-03 Online:2025-02-25 Published:2025-03-07
Contact: Shuang-Yue ZHANG E-mail:hayyzhshy@njmu.edu.cn

摘要/Abstract

摘要： 目的：探讨甲基转移酶样蛋白5（METTL5）在口腔鳞状细胞癌（OSCC）中的表达模式、临床意义及生物学功能。方法：采用生物信息学分析和免疫组织化学染色检测METTL5在OSCC中的表达和定位，揭示METTL5表达与OSCC患者预后之间的关系。通过卡方检验评估METTL5蛋白丰度与OSCC患者临床参数之间的关系。通过CCK-8、克隆形成、划痕及Transwell实验评估Cal27细胞中METTL5沉默后细胞恶性表型的变化。结果：METTL5在OSCC中表达上调，其异常高表达与OSCC患者高病理分级（P=0.033 7），颈淋巴结转移（P=00.013 8）及低生存率显著相关（P＜0.001）。体外敲低METTL5显著抑制Cal27细胞增殖、迁移和侵袭。结论：METTL5促进OSCC进展，可作为生物学标志物预测OSCC患者的预后。

关键词: OSCC, METTL5, 预后

Abstract: Objective:?To determine the expression pattern, clinical significance and biological function of METTL5 in oral squamous cell carcinoma (OSCC). Methods:?Bioinformatic interrogations and immunohistochemical (IHC) staining were utilized for determining the expression and localization of METTL5 in OSCC, and for revealing the relationship between METTL5 expression and prognosis in OSCC patients. The association between the abundance of METTL5 protein and clinicopathological parameters of OSCC patients were evaluated by Chi-square test. CCK-8, colony formation, wound healing and transwell assays were utilized to assess the changes in cellular malignant phenotype after METTL5 silencing in Cal27 cells. Results: METTL5 was upregulated in OSCC, and its aberrant overexpression was positively correlated with high pathological grade, cervical lymph node metastasis and reduced survival in OSCC patients (P=0.0337, 0.0138, P＜0.001). METTL5 knockdown significantly inhibited proliferation, migration and invasion of Cal27 cells. Conclusions:?Our findings reveal that METTL5 promotes OSCC progression and acts as a biomarker to predict prognosis of OSCC patients.

Key words: Oral squamous cell carcinoma, METTL5, Prognosis

冯星雨张伟张双越. METTL5在口腔鳞状细胞癌的表达及功能研究[J]. 口腔生物医学, 2025, 16(1): 20-25.

Yu XingFeng Shuang-Yue ZHANG. Expression and function of METTL5 in oral squamous cell carcinoma[J]. Oral Biomedicine, 2025, 16(1): 20-25.

参考文献 1.

Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma--an update. CA Cancer J Clin. 2015;65(5):401-21.2. Kordbacheh F, Farah CS. Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2021;13(21).3. Gaviraghi M, Vivori C, Tonon G. How Cancer Exploits Ribosomal RNA Biogenesis: A Journey beyond the Boundaries of rRNA Transcription. Cells. 2019;8(9).4. Wang Z, Liu J, Yang Y, et al. Expression and prognostic potential of ribosome 18S RNA m(6)A methyltransferase METTL5 in gastric cancer. Cancer Cell Int. 2021;21(1):569.5. Gu C, Wang Z, Zhou N, et al. Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N(6)-methyladenosine of Notch1. Mol Cancer. 2019;18(1):168.6. Liu ZX, Li LM, Sun HL, et al. Link Between m6A Modification and Cancers. Front Bioeng Biotechnol. 2018;6:89.7. Chen J, Fang X, Zhong P, et al. N6-methyladenosine modifications: interactions with novel RNA-binding proteins and roles in signal transduction. RNA Biol. 2019;16(8):991-1000.8. Li T, Hu PS, Zuo Z, et al. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019;18(1):112.9. Xu Y, Ye S, Zhang N, et al. The FTO/miR-181b-3p/ARL5B signaling pathway regulates cell migration and invasion in breast cancer. Cancer Commun (Lond). 2020;40(10):484-500.10. Li J, Xie H, Ying Y, et al. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. Mol Cancer. 2020;19(1):152.11. Turkalj EM, Vissers C. The emerging importance of METTL5-mediated ribosomal RNA methylation. Exp Mol Med. 2022;54(10):1617-25.12. Sun S, Fei K, Zhang G, et al. Construction and Comprehensive Analyses of a METTL5-Associated Prognostic Signature With Immune Implication in Lung Adenocarcinomas. Front Genet. 2020;11:617174.13. Zhang Z, Zhang C, Yang Z, et al. m(6)A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer. J Hematol Oncol. 2021;14(1):190.14. Rong B, Zhang Q, Wan J, et al. Ribosome 18S m(6)A Methyltransferase METTL5 Promotes Translation Initiation and Breast Cancer Cell Growth. Cell Rep. 2020;33(12):108544.15. Liu X, Ma H, Ma L, et al. The potential role of methyltransferase-like 5 in deficient mismatch repair of uterine corpus endometrial carcinoma. Bioengineered. 2022;13(3):5525-36.16. Huang H, Li H, Pan R, et al. Ribosome 18S m(6)A methyltransferase METTL5 promotes pancreatic cancer progression by modulating c?Myc translation. Int J Oncol. 2022;60(1).17. Chamoli A, Gosavi AS, Shirwadkar UP, et al. Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics. Oral Oncol. 2021;121:105451.18. Chen M, Wong CM. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis. Mol Cancer. 2020;19(1):44.19. Yang B, Wang JQ, Tan Y, et al. RNA methylation and cancer treatment. Pharmacol Res. 2021;174:105937.20. Xia P, Zhang H, Lu H, et al. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression. Cancer Commun (Lond). 2023;43(3):338-64.21. Peng H, Chen B, Wei W, et al. N(6)-methyladenosine (m(6)A) in 18S rRNA promotes fatty acid metabolism and oncogenic transformation. Nat Metab. 2022;4(8):1041-54.22. Dai Z, Zhu W, Hou Y, et al. METTL5-mediated 18S rRNA m(6)A modification promotes oncogenic mRNA translation and intrahepatic cholangiocarcinoma progression. Mol Ther. 2023;31(11):3225-42.